Sign in
CompletedPhase 4

Erector Spinae Plane Block as Pain Management After Lumbar Fusion Surgery

Key facts

Who runs it
Ilse van de Wijgert
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
76 people enrolled
Started
1 Jun 2022
Ended
19 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ropivacaine Hydrochloride Injection
  • Sodium chloride
Record updated
17 April 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Patients planned for elective lumbar spinal fusion surgery with a dorsal surgical approach
  • 1-4 fusion level spine surgery
  • Written informed consent

Who cannot take part

  • Patients who will undergo spine surgery involving less than 2 or more than 4 levels of fusion, scoliosis surgery*
  • Patients who will undergo circumferent spine surgery
  • Patients with an active, local infection or systemic infection
  • Patients with an allergy to one or more medications used in the study
  • Kidney- or liver failure inhibiting the systemic use of paracetamol and/or NSAIDs
  • Patients with a history of drugs or alcohol abuse
  • Cognitive impairment
  • A Body Mass Index (BMI) > 40 kg/m²
  • ASA physical health classification > 3
  • Patients with any contraindication to a regional anesthetic technique
  • Acute surgeries
  • Pregnancy
  • Inability to speak or understand the Dutch language

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Rationale: Lumbar spine surgery is associated with high postoperative pain scores and analgesic use, despite use of multimodal analgesia. The erector spinae plane block (ESPB) is a promising locoregional anesthetic technique for this type of surgery. The literature is not yet conclusive about the effectiveness of this technique on reducing postoperative pain intensity.

Read full original descriptionShow less

Objective: The objective of this study is to evaluate the analgesic effect of ESPB as add-on therapy to multimodal analgesia on early postoperative pain intensity after lumbar spinal fusion surgery compared to placebo.

Study design: The study is designed as a prospective mono-centre, randomized, double-blinded, placebo-controlled trial.

Study population: 76 patients ≥ 18 years of age requiring elective lumbar spinal fusion surgery involving one to four fusion levels.

Intervention: Patients will receive ultrasound-guided ESPB with either ropivacaine or placebo at the end of surgery.

Main study parameters/endpoints: Main study parameter is pain intensity upon emergence from anesthesia measured with the Numeric Rating Scale. A minimal clinically important difference is considered to be a decrease of 1.5 points. Secondary endpoints are pain intensity during hospital stay and after 30 days, opioid use during hospital stay and after 30 days, opioid side effects, use of anti-emetics, time to first opioid use/request, length of hospital stay, quality of recovery at discharge.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The Sint Maartenskliniek is experienced in applying locoregional analgesia, the use of ropivacaine and using sonography. The procedure of administering ESPB has a very low risk of complications. Receiving placebo is justifiable because this group will not be withhold standard treatment. The risks of receiving placebo are negligible. The patients will visit the clinic at regular follow-up moments.

The 2 groups in the trial

  • ESPB with ropivacaineTreatment being tested

    Patients in the experimental group will receive locoregional analgesia via ESPB with injectate consisting of ropivacaine 0.375 mg/mL with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra (total dose of 225 mg).

    Treatment: Ropivacaine Hydrochloride Injection

  • ESPB with placeboPlacebo, for comparison

    Patients in the placebo group will receive an injection performed as the procedure of ESPB with injectate consisting of sodiumchloride 0.9% with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra.

    Treatment: Sodium chloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Erector Spinae Plane Block for Reduction of Early Postoperative Pain Scores and Opioid Use in Lumbar Spinal Fusion Surgery, a Prospective Double-blinded Randomized Placebo-controlled Trial
Record updated
17 April 2024